OKAST has joined the UHD World Association (UWA) and will integrate the association’s HDR Vivid and Audio Vivid technologies into its OTT platform ecosystem, as it targets further expansion across ...

OpenAI launched Frontier, a platform for building and governing enterprise AI agents, as companies increasingly question whether to commit to single-vendor systems or maintain multi-model flexibility.

Telehealth company Hims & Hers has added Grail’s blood cancer test Galleri to its offerings as the medtech has now sent off data for a potential FDA approval. Galleri works as a simple blood test that ...

The Golden State Warriors have gone all in on a Giannis Antentokumpo trade and this most recent report proves it. Ben Rogers breaks down why this new development regarding Draymond Green shows that ...

Bioxytran's lead antiviral program, ProLectin‑M, is being developed under an active U.S. FDA Investigational New Drug (IND) framework, as previously announced by the Company. In May 2025, Bioxytran ...

The makers of the Naya Create modular split keyboard are back with a new modular keyboard system. This time instead of a split keyboard though, they’ve built a new premium low-profile mechanical ...

Wonder, a mealtime platform that allows customers to order from multiple restaurants in a single transaction, will open its newest location on Friday, Jan. 9, in Warren County. The business will hold ...

Dow Jones will integrate Polymarket’s real-time prediction market data across its major financial news platforms. Dow Jones said Wednesday it has entered an exclusive partnership with Polymarket to ...

“We believe OmicInsight’s best-in-market spatial omics imaging technology and its strategic pivot to translational research and AI platform will drive significant impact in the pharmaceutical industry ...

Reolink will showcase its next-generation AI-driven security technology at CES 2026, offering attendees an early look at new on-device intelligence, multi-lens camera systems, and sustainable ...

Initiate Moderna with a Hold rating at a $25 target price (lower than the current price), citing balanced risk-reward despite the advanced mRNA platform and robust pipeline. MRNA's near-term execution ...